Portfolio
We seek investments in innovative companies that are developing first-in-class products for growth markets. Investments have been made in various therapeutic areas, including oncology, inflammation, cardiovascular, metabolic and CNS.
Fibrex Medical - Austria | |||
| Fund engagement: | 2006 | Activity: | Drug development Reperfusion injury |
| Status: | Exited - Licensing | Contact: | www.fibrexmedical.com |
Elara Phamraceuticals - Germany | |||
| Fund engagement: | 2006 | Activity: | Drug development HIF pathway |
| Status: | Pre-clinical development | Contact: | www.elarapharma.com |
Lipid Therapeutics - Germany | |||
| Fund engagement: | 2008 | Activity: | Drug development Colitis ulcerosa |
| Status: | Partnered - Phase IIB | Contact: | www.lipid-therapeutics.com |
Affectis Pharmaceuticals - Germany | |||
| Fund engagement: | 2005 | Activity: | Drug development Depression |
| Status: | Clinical phase IIA | Contact: | www.affectis.com |
Immatics - Germany | |||
| Fund engagement: | 2004 | Activity: | Drug development Cancer vaccines |
| Status: | Clinical phase IIA | Contact: | www.immatics.com |
Endoart - Switzerland | |||
| Fund engagement: | 2006 | Activity: | Medtech Obesity |
| Status: | Exited - Aquisition | Contact: | n.a. |
Vasopharm - Germany | |||
| Fund engagement: | 2006 | Activity: | Drug development Traumatic brain injury |
| Status: | Clinical phase IIA | Contact: | www.vasopharm.com |
Hybricore - Germany | |||
| Fund engagement: | 2003 | Activity: | Services Antibody production |
| Status: | Exited - Licensing | Contact: | n.a. |
Combinature - Germany | |||
| Fund engagement: | 2006 | Activity: | Drug development Anti-infectives |
| Status: | Exited - Secondary transaction | Contact: | n.a. |
Jado Technologies - Germany | |||
| Fund engagement: | 2006 | Activity: | Drug development Allergy |
| Status: | Clinical phase IIA | Contact: | www.jado-tech.com |
Cenix Bioscience - Germany | |||
| Fund engagement: | 2002 | Activity: | Services RNAi based target discovery |
| Status: | Profitable | Contact: | www.cenix-bioscience.com |
ArthroKinetics - Germany | |||
| Fund engagement: | 2003 | Activity: | Medtech Cartilage replacement |
| Status: | Exited - IPO | Contact: | www.arthro-kinetics.com |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
"The EMBL Ventures team stands out through its professional competence, loyalty, consistency and intense interest in the development of Fibrex. As a consequence, convincing solutions are found in a timely fashion, even in difficult situations. EMBL Ventures offers access to its broad scientific and industry network, which is a tremendous support to achieve our company goals."
Dr. Rainer Henning; CEO, Fibrex Medical, Vienna